FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average	burden					
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Levin Adam				2. Issuer Name and Ticker or Trading Symbol Ensysce Biosciences, Inc. [ENSC]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner				
(Last) (First) (Middle) C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022						-	Officer (giv	e title below)	Oth	er (specify belo	w)	
(Street) LA JOLLA, CA 92037			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acqui						es Acquir	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		Execution Date, if any (Month/Day/Year)			8)	4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5) (A) or Amount (D)		of (D) C T (I	Owned Following Reported Transaction(s) (Instr. 3 and 4)		d	Ownership Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Derivative Conversion 1		3. Transaction Date Execution Date, if (Month/Day/Year) (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number 6. Don of Derivative Exp			Date Exercisable and 7 xpiration Date of Month/Day/Year) S		7. Title and Amount of Underlying Securities		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)	
				Code	V	(A)	(D)	Date Exercisab		iration	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option	\$ 0.425	06/23/2022		A		15,000		(1)	06/2	23/2032	Comm	115 000	(1)	35,000	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Levin Adam C/O ENSYSCE BIOSCIENCES, INC. 7946 IVANHOE AVENUE, SUITE 201 LA JOLLA, CA 92037	X					

Signatures

/s/ Adam Levin	06/27/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On June 23, 2022, Mr. Levin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value \$0.0001 (1) per share, with a per share exercise price of \$0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.